The ENSEMBLE Study with Janssen’s Ad26.COV2.S Investigational Vaccine

The Ad26.COV2.S investigational vaccine is being developed to prevent or lessen the severity of COVID-19, the disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The Ad26.COV2.S investigational vaccine includes bits of genetic material copied from the spikes of the SARS-CoV-2 virus. The goal is for the body to be immunized against COVID-19. The investigational vaccine does not contain the actual virus and cannot cause COVID-19. The ENSEMBLE study aims to test Janssen’s investigational vaccine in many different populations across the globe.

Visit - NCT04505722 for additional details about the Janssen COVID-19 vaccine clinical study.

What You Need To Know About The Johnson & Johnson (J&J)/Janssen Vaccine 

The J&J/Janssen vaccine requires 1 dose to prevent COVID-19 disease, hospitalization, and death. Independent experts who reviewed the safety data have concluded that the vaccine is safe.  

Read more about the J&J/Janssen vaccine.

Together we can help end uncertainty. Join us.

We need your help to keep learning and improving vaccines against COVID-19. We made history with safe and effective vaccines and we’ll keep working as long as there are people to protect, variants emerging, and research answers needed to end this pandemic. To participate:

  • Fill out the survey again so we have your most current information to match you with a study, even if you filled it out previously!
  • If you haven’t registered to volunteer before, sign up today. There’s still a lot we can do together for those we love.


Content last reviewed on July 15, 2021